Amgen Inc.

Vatee Pattaropong

Paul John Dransfield

Jonathan B Houze

Zhihua Ma

Zice Fu

Su-Jen Lai

Julie Anne Heath

Julio Cesar Medina

Nobuko Nishimura

David John Kopecky

Mikkel V Debenedetto

Gayathri Swaminath

Xiaohui Du

Xiaoqi Chen

Xiaodong Wang

Richard V Connors

Steven H Olson

Ning Chen

Jeffrey Thomas Mihalic

Alan C Cheng

Yinhong Chen

Aarif Yusuf Khakoo

Wen-Chen Yeh

Jeffrey Deignan

Kevin Chao Yang

Matthew R Kaller

Ted Charles Judd

Daniel B Horne

Simon J Hedley

Lawrence R McGee

James S Harvey

Frank Kayser

Robert P Farrell

Sean P Brown

Todd J Kohn

Jiwen Liu

Yingcai Wang

Marc Vimolratana

Wang Shen

Liusheng Zhu

Ming Yu

Philip Dean Ramsden

Matthew Irvine Brown

Timothy David Cushing

Felix Gonzalez Lopez De Turiso

Charles Kreiman

An-Rong Li

Lars V Heumann

Michael J Schmitt

Xian Yun Jiao

SuJen Lai

Malgorzata Wanska

Ankit Sharma

Jillian L Simard

Yi Heng Chen

Jian Luo

Rajiv Sharma

Michael G Johnson

Youngsook Shin

Xiao He

Zhongyu Wang

Jie Zhang

David C Moebius

Jennifer L Seganish

Jinqian Liu

YuMei Xiong

Julia Winslow Lohman

XianYun Jiao

Yongli Su

Margrit Schwarz

Yong-Jae Kim

Jeffrey D Reagan

Qiong Cao

Daniel Lin

Li Yang

Sujen Lai

Matthew Brown

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: Figure I and Figure II where the definitions of the variables are provided herein.

Substituted pyrimidinones as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor. Such compounds include those selected from 

Bromotriazole intermediates

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Growing community of inventors

Bedford, MA, United States of America

Vatee Pattaropong